drugset / Trial / NCT00139828
Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
In this postmarketing study, the safety of Nonafact® (human coagulation factor IX) is evaluated in previous treated and untreated patients with severe, moderate or mild haemophilia B.
Timeline
- Start
- 2003-05
- Primary completion
- —
- Completion
- 2007-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | COAGULATION FACTOR IX HUMAN | Protein / enzyme biologic | — | — |